

**Celadon Pharmaceuticals Plc**

**("Celadon" or the "Company" or the "Group")**

**Second Admission of Shares**

**London, 07 June 2024** - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, is pleased to announce that further to the announcement on 10 May 2024, application for the admission of 238,095 new ordinary shares to trading on AIM (the "**Second Admission**") has been made. It is expected the shares will be admitted to trading on 11 June 2024.

The remaining 476,191 shares are due to be admitted in two further instalments on 15 July and 12 August 2024.

The Company advises that on Admission the Company's issued share capital will consist of 65,982,712 Ordinary Shares, with one voting right each. The Company does not hold any shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 65,982,712. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

**Enquiries:**

**Celadon Pharmaceuticals Plc**

James Short

Via Powerscourt

Jonathan Turner

**Canaccord Genuity Limited (Nominated Adviser and Broker)**

Bobbie Hilliam / Andrew Potts

+44 (0)20 7523 8000

**Global Investment Strategy UK Limited (Joint Broker)**

James Sheehan

+44 (0)20 7048 9400

**Powerscourt Group**

Sarah MacLeod / Nick Johnson / Sam Austrums

+44 (0)20 7250 1446

**About Celadon Pharmaceuticals Plc**

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its GMP pharmaceutical cannabis product. The Group owns an approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website [www.celadonpharma.co.uk](http://www.celadonpharma.co.uk)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FURVQLFBZQLZBBV